FOXA1 and neoplasm: WU et al.[29 ▶] have disclosed that suberoylanilide hydroxamic acid inhibits HDAC8/FOXA1 signals in the epithelial-mesenchymal transition of cancer cells and introduced this acid as an anti-tumor agent for the treatment of TNBC cancer.